- Home
- DMAC vs BHR Comparison
DMAC vs BHR Comparison
Compare DMAC & BHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- BHR
- Stock Information
- Founded
- DMAC 2000
- BHR 2013
- Country
- DMAC United States
- BHR United States
- Employees
- DMAC N/A
- BHR N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- BHR Real Estate Investment Trusts
- Sector
- DMAC Health Care
- BHR Real Estate
- Exchange
- DMAC Nasdaq
- BHR Nasdaq
- Market Cap
- DMAC 178.0M
- BHR 171.0M
- IPO Year
- DMAC N/A
- BHR N/A
- Fundamental
- Price
- DMAC $3.76
- BHR $2.55
- Analyst Decision
- DMAC Strong Buy
- BHR
- Analyst Count
- DMAC 2
- BHR 0
- Target Price
- DMAC $8.00
- BHR N/A
- AVG Volume (30 Days)
- DMAC 307.4K
- BHR 285.7K
- Earning Date
- DMAC 08-06-2025
- BHR 07-31-2025
- Dividend Yield
- DMAC N/A
- BHR 7.84%
- EPS Growth
- DMAC N/A
- BHR N/A
- EPS
- DMAC N/A
- BHR N/A
- Revenue
- DMAC N/A
- BHR $723,586,000.00
- Revenue This Year
- DMAC N/A
- BHR N/A
- Revenue Next Year
- DMAC N/A
- BHR $2.32
- P/E Ratio
- DMAC N/A
- BHR N/A
- Revenue Growth
- DMAC N/A
- BHR N/A
- 52 Week Low
- DMAC $2.80
- BHR $1.80
- 52 Week High
- DMAC $6.82
- BHR $3.95
- Technical
- Relative Strength Index (RSI)
- DMAC 47.18
- BHR 56.93
- Support Level
- DMAC $3.48
- BHR $2.44
- Resistance Level
- DMAC $3.99
- BHR $2.58
- Average True Range (ATR)
- DMAC 0.32
- BHR 0.12
- MACD
- DMAC -0.00
- BHR -0.01
- Stochastic Oscillator
- DMAC 41.01
- BHR 53.12
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About BHR Braemar Hotels & Resorts Inc.
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.